S-P extends HuCAL access deal with MorpoSys

25 May 2008

US drugmaker Schering-Plough has exercised its option to continue its alliance with German antibody specialist MorphoSys for another year.

Announced in 2006 (Marketletter May 22, 2006) and extendable until 2011, the deal allows Schering-Plough access to MorphoSys' proprietary antibody library, HuCAL GOLD, along with development and commercialization rights to any resulting marketed antibodies. In return, MorphoSys recieves royalties, milestones and license fees on the products, as well as annual user fees for HuCAL.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight